8-KLeadership Changes

Merck & Co., Inc. 8-K Report, Executive Changes (Sep 19, 2008)

Filed September 19, 2008For Securities:MRK

Summary

This 8-K filing from Merck & Co., Inc. (MRK), filed on September 19, 2008, pertains to actions taken by the Compensation Committee of Schering-Plough's Board of Directors regarding the compensation of Dr. Thomas P. Koestler, Executive Vice President & President of Schering-Plough Research Institute. The report details adjustments to Dr. Koestler's base salary, annual incentive target, and a special stock award, effective in late 2008 and early 2009. These compensation changes are explicitly linked to Dr. Koestler's strong performance in a critical research and development role and the competitive landscape for executive talent. The stock award, in particular, includes a multi-year vesting period tied to research and development initiatives and continued employment, emphasizing retention and long-term commitment to the company's strategic goals. Investors should note that these actions are specific to Schering-Plough and its executive compensation, which, at the time of this filing, would be relevant in the context of any ongoing or potential business interactions or mergers between Merck and Schering-Plough.

Key Highlights

  • 1Schering-Plough's Compensation Committee adjusted compensation for Dr. Thomas P. Koestler, EVP & President of Research Institute.
  • 2Effective October 1, 2008, Dr. Koestler's base salary increased by 5% to $864,000.
  • 3Effective January 1, 2009, his target annual incentive increased from 70% to 80% of base salary.
  • 4A special service- and performance-based stock award of 250,000 Schering-Plough common shares was granted on October 1, 2008.
  • 5The stock award is subject to R&D initiative performance and a four-year retention requirement (until October 1, 2012).
  • 6These actions are a recognition of Dr. Koestler's strong performance and retention strategy amidst competition for executive talent.
  • 7All other terms of Dr. Koestler's December 19, 2006 employment agreement remain unchanged.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose material changes to the compensation of a key executive, Dr. Thomas P. Koestler, within Schering-Plough, a company that had a significant relationship with Merck & Co. at the time.

The compensation adjustments and the stock award were made by Schering-Plough's Compensation Committee to recognize Dr. Koestler's strong performance in a critical research and development role and to address the competitive market for executives with his expertise and stature, thereby encouraging retention.

Dr. Koestler was granted a special stock award of 250,000 Schering-Plough common shares. The award is contingent upon achieving certain research and development milestones between October 1, 2008, and September 30, 2012, and requires Dr. Koestler to remain employed by Schering-Plough through October 1, 2012, for full vesting and receipt of the shares.

This filing specifically details compensation changes for an executive at Schering-Plough. While Merck and Schering-Plough had a significant relationship, and a merger was eventually completed, this particular 8-K is focused on Schering-Plough's internal executive compensation decisions and not Merck's consolidated financial performance directly. Investors should consider it in the context of Schering-Plough's operational and strategic incentives at that time.